Table 1 Baseline clinical features of patients
Variable | xinruibai group (N = 53) | Filgrastim group (N = 33) | t/χ2 value | P value |
|---|---|---|---|---|
Age | 6.26 ± 3.05 | 7.30 ± 3.27 | 1.46 | 0.1467 |
Gender n (%) | 0.16 | 0.681 | ||
Male | 35 (66.0) | 24 (72.7) | ||
Female | 18 (34.0) | 9 (27.3) | ||
Disease n (%) | 2.54 | 0.198 | ||
Aplastic anemia | 2 (3.8) | 3 (9.1) | ||
Leukemia | 2 (3.8) | 6 (18.1) | ||
Thalassemia major | 46 (86.8) | 24 (72.7) | ||
Mucopolysaccharidosis | 3 (5.7) | 0 (0.0) | ||
Pre-treatment scheme n(%) | 2.01 | 0.215 | ||
BU + CTX + ATG | 4 (7.5) | 4 (12.1) | ||
CTX + ATG + TBI | 1 (1.9) | 2 (6.1) | ||
FLU+CTX + ATG | 48 (90.6) | 27 (81.8) | ||
Number of infused CD34 + cells | 6.19 ± 2.31 | 5.26 ± 1.95 | 1.92 | 0.051 |